Ostatnia aktualizacja :
28/04/2024
Antyarytmik   Verapamil hydrochloride  
Injekcje
Roztwór doustny
Trwałość roztworów Trwałość w mieszaninie Czynnik wpływający na trwałość Zgodność Sposób podania Bibliografia Pdf
   Struktura chemiczna  

Nazwa handlowa   Nazwa handlowa     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Calaptin Indie
Calovera Indie
Cordilox Wielka Brytania
Dilacoran Meksyk
Filacard Niemcy
Flamon Szwajcaria
Geangin Dania
Isocor Rumunia
Isoptin Arabia Saudyjska, Australia, Austria, Egipt, Grecja, Holandia, Niemcy, Nowa Zelandia, Polska, Portugalia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Włochy
Isoptina Chile
Isoptine Belgia, Francja , Luksemburg
Izoptomil Egipt
Lekoptin Iran
Manidon Hiszpania
Palyuan Meksyk
Securon Wielka Brytania
Serriten Meksyk
Unimylo Meksyk
Vasolan Japonia
Verahexal Niemcy
Veraloc Dania
Veramex Niemcy
Verapabene Austria
Verapam Szwajcaria
Verapamil Kanada, Niemcy, Stany Zjednoczone Ameryki, Szwecja, Węgry
Verapamilo Argentyna, Chile, Ekwador, KolumbiaKolumbia, Peru
Verpamil Finlandia, Malezja
Bibliografia   Injekcje   Bibliografia : Verapamil hydrochloride  
Typ Publikacja
62 Czasopismo Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
191 Czasopismo Riley CM.
Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.
Am J Hosp Pharm 1988 ; 45: 2079-2091.
242 Czasopismo Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M.
Stability of amiodarone hydrochloride in admixtures with other injectable drugs.
Am J Hosp Pharm 1986 ; 43: 917-921.
288 Czasopismo Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
300 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
364 Czasopismo Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ.
Compatibility of aminophylline and verapamil in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 97-100.
371 Czasopismo Thompson DF, Stiles ML, Allen LV, Tu YH.
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 142-145.
372 Czasopismo Johnson CE, Lloyd CW, Aviles AI, Rybarz KL.
Compatibility of premixed theophylline and verapamil intravenous admixtures.
Am J Hosp Pharm 1988 ; 45: 609-612.
398 Czasopismo Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
660 Czasopismo Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
706 Czasopismo Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231.
921 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1041 Czasopismo Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1045 Czasopismo Das Gupta V, Stewart KR.
Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections.
Am J Hosp Pharm 1984 ; 41: 686-689.
1057 Czasopismo Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1098 Czasopismo Cutie MR.
Verapamil precipitation.
Ann Intern Med 1983 ; 98: 672.
1099 Czasopismo Tucker R, Gentile JF.
Precipitation of verapamil in an intravenous line.
Ann Intern Med 1984 ; 101: 880.
1100 Czasopismo Bar-Or D, Kulig K, Marx JA, Rosen P.
Precipitation of verapamil.
Ann Intern Med 1982 ; 97: 619.
1232 Czasopismo Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1351 Czasopismo Tucker R, Gentle JF.
Precipitation of verapamil with nafcillin.
Am J Hosp Pharm 1984 ; 41: 2588.
1508 Czasopismo Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1625 Czasopismo Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Czasopismo Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1712 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Czasopismo Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1803 Czasopismo Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Czasopismo Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 Czasopismo Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1964 Czasopismo Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2018 Czasopismo Veggeland T.
Visual compatibility of clonidine with selected drugs.
Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087 Czasopismo Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Czasopismo Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2328 Laboratorium Sugammadex (Bridion®) – Résumé des caractéristiques du produits
Organon 2009
3766 Czasopismo Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3824 Czasopismo Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3934 Laboratorium Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
4130 Czasopismo Koller AK, Krebs S, Dörje F.
Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen.
Pharmaceutics 2021 , 13, 21.
4603 Czasopismo Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Czasopismo Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales